title: Effect of Single Intravitreal Bevacizumab on Ophthalmic and Middle Cerebral Arterial Blood Flow in Retinopathy of Prematurity.
abstract: OBJECTIVE
  To evaluate the effect of a single intravitreal bevacizumab (IVB) injection on blood flow parameters in the ophthalmic artery (OA) and middle cerebral artery (MCA) in infants with retinopathy of prematurity (ROP).
  
  
  METHODS
  This prospective and interventional study included 15 infants with ROP who were treated with IVB. Peak systolic velocity (PSV), end-diastolic velocity, mean velocity (MV) and resistivity index were measured using pulse wave Doppler ultrasonography (Philips En Visor C, Amsterdam, The Netherlands) in the OA and MCA, before IVB injection and 1 day, 1 week and 1 month after IVB injection.
  
  
  RESULTS
  Measurements of PSV-OA, MV-OA and PSV-MCA showed significant changes after IVB treatment (p = 0.01, p = 0.02, p = 0.02, respectively). The PSV-OA measurements at 1 week and 1 month were significantly lower than the baseline PSV-OA measurement (p = 0.03 and p = 0.01, respectively). The MV-OA measurement was significantly lower at 1 month following IVB as compared to the baseline MV-OA measurement (p = 0.03). The PSV-MCA showed a significant decline 1 day after IVB injection (p = 0.03).
  
  
  CONCLUSIONS
  The study demonstrated that IVB causes significant alterations in blood flow parameters in the OA and MCA predicted by Doppler ultrasonography in infants with ROP.
authors.affiliation: Department of Ophthalmology, Zeynep Kamil Maternity and Children's Diseases Training and Research Hospital, Istanbul, Turkey.
authors.forename: Murat
authors.initials: M
authors.lastname: Gunay
authors.forename: Abdulhamit
authors.initials: A
authors.lastname: Tuten
authors.forename: Selim
authors.initials: S
authors.lastname: Sancak
authors.forename: Gokhan
authors.initials: G
authors.lastname: Celik
authors.forename: Handan
authors.initials: H
authors.lastname: Bardak
authors.forename: Emre
authors.initials: E
authors.lastname: Dincer
authors.forename: Guner
authors.initials: G
authors.lastname: Karatekin
authors.forename: Gurkan
authors.initials: G
authors.lastname: Erdogan
authors.forename: Yavuz
authors.initials: Y
authors.lastname: Bardak
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000068258:Bevacizumab / Q000008:administration & dosage*; D001783:Blood Flow Velocity / Q000187:drug effects / Q000502:physiology; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D058449:Intravitreal Injections; D008297:Male; D020768:Middle Cerebral Artery / Q000000981:diagnostic imaging / Q000187:drug effects* / Q000503:physiopathology; D009880:Ophthalmic Artery / Q000000981:diagnostic imaging / Q000187:drug effects* / Q000503:physiopathology; D011446:Prospective Studies; D012039:Regional Blood Flow / Q000187:drug effects; D012178:Retinopathy of Prematurity / Q000188:drug therapy* / Q000503:physiopathology; D018615:Ultrasonography, Doppler, Color
chemical_list: D020533:Angiogenesis Inhibitors; D000068258:Bevacizumab